Get the Stockscreener App
30.17
3.76%
-1.18
After Hours:
30.17
Kymera Therapeutics Inc Stock (KYMR) Latest News
Kymera Therapeutics announces new performance-based stock plan - Investing.com
Rhumbline Advisers Acquires 1,861 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Q3 Earnings Forecast for KYMR Issued By HC Wainwright - Defense World
Analysts Set Expectations for KYMR Q2 Earnings - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Annual Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 at HC Wainwright - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Announces Earnings Results - MarketBeat
Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 13.9% on Disappointing Earnings - MarketBeat
(KYMR) Trading Signals - Stock Traders Daily
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Volatility Hits 9.22%: What Good Investors Need To Be Aware Of - Stocks Register
Kymera Therapeutics stock target cut to $54 by H.C. Wainwright - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript - Insider Monkey
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus.com
Demystifying Kymera Therapeutics: Insights From 6 Analyst Reviews - Benzinga
We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Reaches New 52-Week Low After Earnings Miss - Defense World
Kymera Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Kymera stock hits 52-week low at $29.23 amid market challenges - Investing.com
Kymera stock hits 52-week low at $29.23 amid market challenges By Investing.com - Investing.com South Africa
Kymera Therapeutics misses Q4 estimates, shares dip By Investing.com - Investing.com Australia
Kymera Therapeutics misses Q4 estimates, shares dip - Investing.com
Kymera Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls -February 27, 2025 at 08:54 am EST - Marketscreener.com
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
KYMERA THERAPEUTICS Earnings Results: $KYMR Reports Quarterly Earnings - Nasdaq
Earnings Flash (KYMR) Kymera Therapeutics Posts Q4 Revenue $7.4M, vs. FactSet Est of $14.4M - Marketscreener.com
Kymera Therapeutics, Inc. SEC 10-K Report - TradingView
Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
Can Kymera's $851M War Chest Deliver on Its Promising Immunology Pipeline Despite Widening Losses? - StockTitan
What To Expect From Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings - Yahoo Finance
Kymera Therapeutics to Participate in Upcoming March Investor Conferences - The Manila Times
Kymera Therapeutics Sets Investor Conference Calendar: Four Key Healthcare Events Where You'll Hear Their Story - StockTitan
Head to Head Analysis: Kymera Therapeutics (NASDAQ:KYMR) and Creative Medical Technology (NASDAQ:CELZ) - Defense World
Assured Guaranty, Kymera rise; BP, Helen of Troy fall, Tuesday, 7/9/2024 - MSN
Kymera Therapeutics (KYMR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance - MSN
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27 - The Manila Times
Kymera Therapeutics (KYMR) Expected to Announce Earnings on Thursday - Defense World
Kymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line (KYMR) - Seeking Alpha
When the Price of (KYMR) Talks, People Listen - Stock Traders Daily
Getting In Cheap On Kymera Therapeutics, Inc. (NASDAQ:KYMR) Is Unlikely - Simply Wall St
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Kymera rises after presentation at the J.P. Morgan event - MSN
SG Americas Securities LLC Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Jennison Associates LLC Trims Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Head to Head Review: Kymera Therapeutics (NASDAQ:KYMR) & Gene Biotherapeutics (OTCMKTS:CRXM) - Defense World
Financial Snapshot: Analyzing Kymera Therapeutics Inc (KYMR)’s Key Ratio Metrics - The Dwinnex
Long Term Trading Analysis for (KYMR) - Stock Traders Daily
SG Americas Securities LLC Cuts Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Kymera Therapeutics to Participate in Upcoming February Investor Conferences - The Manila Times
Inside Kymera's Upcoming Biotech Presentations: Key Investor Events You Can't Miss - StockTitan
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):